Research suggests that the medication, a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, originally developed to manage Type 2 diabetes, may be able to treat a wide range of conditions involving impulse control, like binge eating disorder.But although there may be tantalizing clues for helping patients with unwanted impulses, GLP-1 and GIP inhibitors may not be optimally designed to treat them sufficiently and need further research, according to a case study from the Perelman School of Medicine at the University of Pennsylvania, published today in Nature Medicine
Read stories about more of the Universitys bright stars
Gottesman MM
[DOI] [PMC free article] [PubMed] [Google Scholar] 76.Nakagami H, Cui TX, Iwai M, Shiuchi T, Takeda-Matsubara Y, Wu L, Horiuchi M
Upper arm: This site is best for young or middle-aged adults
Dock foredragar vissa utovare att injicera nara skadeplatsen (subkutant eller intramuskulart) for lokala koncentrationsfordelar, sarskilt for sen- och ligamentskador